The European Medicines Authority’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for a new drug to treat hereditary angioedema (HAE).
Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to ...
ORLANDO -- An orally disintegrating tablet form of sebetralstat (Ekterly) for young children with hereditary angioedema (HAE) showed similar results as the non-disintegrating tablet used in adults, a ...
Short-term prophylaxis (STP) is used to minimize the risk of a hereditary angioedema (HAE) attack in cases in which known HAE attack triggers cannot be avoided. This is most often the case with ...
– ORLADEYO oral granules demonstrated early and sustained reduction in HAE attacks over one year of treatment in second interim analysis of APeX-P – – ORLADEYO oral granules are currently under review ...
Dec 12 (Reuters) - The U.S. Food and Drug Administration has expanded the use of BioCryst Pharmaceuticals' drug to include an oral pellet formulation for preventing hereditary angioedema attacks ...
Stocktwits on MSN
KalVista Pharmaceuticals stock rallies after hours on strong genetic disorder drug sales kickstart
KalVista launched Ekterly in the U.S. in July for the treatment of acute attacks of hereditary angioedema in adults and ...
Like angioedema in general, hereditary angioedema (HAE) is characterized by subcutaneous or submucosal edema that is nonpruritic — ie, does not itch — and nonpitting — ie, does not leave an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback